By Dean Seal
Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong.
The medical-technology company posted a profit of $385.6 million, or 65 cents a share, up from $369.9 million, or 61 cents a share, in the same quarter a year ago.
Stripping out one-time items, adjusted earnings were 59 cents a share. Analysts polled by Factset had been expecting 55 cents a share.
Sales jumped 9% to $1.39 billion, topping analyst projections for $1.36 billion, according to FactSet.
The Irvine, Calif., company said the top-line growth was driven by strong demand for its transcatheter aortic valve replacements and repair and replacement technologies for both mitral and tricuspid valves.
For the first quarter of 2025, the company expects adjusted earnings of 58 cents to 64 cents a share on $1.35 billion to $1.43 billion in revenue. That's in line with analyst views for adjusted earnings of 59 cents a share on $1.41 billion in revenue.
The stock rose 6.7% to $75.69 in postmarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 11, 2025 17:07 ET (22:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。